INTRODUCTION
Chronic hepatitis B virus (HBV) infection is the main cause of hepatocellular carcinoma (HCC). 1 Although it has been reported that up to 40% of HBV-related HCC develops in patients who do not have cirrhosis, almost all cases of chronic hepatitis C virus (HCV) related HCC occur in cirrhotic liver. 1 In most cases of HCC which originate from cirrhotic liver, hepatic fibrosis might be one of the early changes of hepatocarcinogenesis because cirrhotic changes of the liver could be resulted from accumulation and exacerbation of fibrosis. 2 On the other hand, it has been demonstrated that HCC patients with advanced fibrosis had shorter overall survival periods than those without it. 3 The fibrosis score is recommended for tumor-node-metastasis staging of HCC. 4 In addition, the Barcelona Clinic Liver
Cancer (BCLC) classification integrated several prognostic factors including portal hypertension which is related to hepatic fibrosis. 5 Therefore, the accurate evaluation of hepatic fibrosis is necessary not only for determining the plan of antiviral therapy but also for the prognostic value in patients with HCC. The gold standard for assessment of hepatic fibrosis has been liver biopsy. 6 However, over-or underestimation of fibrosis can be possible due to intra-and interobserver variability and sampling errors. 7, 8 Several limitations, such as invasiveness, risk of complication, and the availability of expert practitioners, hamper the clinical use of liver biopsy especially when repeated tests are required. 9 The current diagnostic strategy for HCC mostly depends on imaging modalities without liver biopsy. 10 Assessment modalities of hepatic fibrosis status without biopsy are required to help predict the prognosis of patients with HCC. Consequently, alternative noninvasive methods based on imaging studies 11, 12 and biochemical tests [13] [14] [15] [16] have been suggested as markers of hepatic fibrosis. However, these tests are not able to fully replace liver biopsy due to the high cost or low diagnostic accuracy. 17 Recently, a simple, accurate, and noninvasive test for hepatic fibrosis known as P2/MS was developed. 17 It uses only simple laboratory tests, i.e., complete blood cell counts. 17, 18 It was found to have high diagnostic accuracy for reflecting hepatic fibrosis and low cost. The favorable qualities of P2/MS were reconfirmed by an external validation. 16 Its clinical application for detecting esophageal varices was assessed by a prospective study. 19 However, P2/MS was developed and validated in virus-related chronic liver disease (CLD) patients without HCC. [17] [18] [19] The applicability of P2/MS in patients with HCC has not yet been validated. In this study, we aimed to validate the diagnostic accuracy of P2/MS and compare it to those of other noninvasive fibrosis scoring systems in patients with HCC.
PATIENTS AND METHODS

Patients
This is a retrospective cohort study. We initially enrolled 177
consecutive HCC patients who underwent surgical resection at Seoul National University Hospital, Seoul, Korea, between June 2007 and March 2009. We excluded six patients whose surgical specimens were not available for evaluating the fibrosis grade of non-tumorous liver parenchyma. A total of 171 patients were included in this study. HCC was diagnosed by imaging modalities with/without alpha-fetoprotein levels based on the American Association for the Study of Liver Diseases guidelines. 10 Tumor staging was performed in accordance with the American Joint Committee on Cancer (AJCC) staging system 6th edition. 4 This study was reviewed and approved by the Institutional Review Board of Seoul National University Hospital.
P2/MS and Other noninvasive fibrosis scoring systems
Laboratory data were acquired from the included patients' medical records. All noninvasive fibrosis scoring systems were calculated using pre-operative laboratory data. The P2/MS values and other noninvasive fibrosis scoring systems were calculated with a previously published formula as following. 
Statistical analysis
Spearman's rank correlation coefficient was calculated to measure the correlation between P2/MS scores and the degree of fibrosis. Receiver operating characteristic (ROC) curves were constructed and the area under the ROC curve (AUROC) was calculated to assess the diagnostic accuracy of P2/MS. The AUROC of P2/MS for detecting significant fibrosis, severe fibrosis, and histological cirrhosis were calculated. The sensitivity, specificity, positive likelihood ratio (PLR), and negative likelihood ratio (NLR) were then calculated using the ROC curves at different cut-off points. All analyses were 
RESULTS
Patient characteristics
The patient characteristics are summarized in Table 1 (Fig. 2) . The sensitivity, specificity, PLR, and NLR of P2/MS were calculated using previously published cut-off values (Table 2) . 17 for detecting histological cirrhosis (F4).
Comparison of P2/MS and other noninvasive fibrosis scoring systems
Mean values of noninvasive fibrosis scoring systems were summarized in Table 3 . To evaluate the diagnostic value of noninvasive fibrosis scoring systems for significant fibrosis, we compared the AUROC of P2/MS with those of other tests (Table 4 (Fig. 3B, Table 5 ).
DISCUSSION
The principal findings of this study relate to the detection of For histological cirrhosis (METAVIR F4), the diagnostic accuracy was greatest for P2/MS among noninvasive fibrosis scoring systems and there was a statistically significant difference between that of P2/MS and AAR.
The early detection of hepatic fibrosis is important for predicting clinical outcomes of patients with HCC. 4 In addition, hepatic fibrosis is a determinant factor for the antiviral therapy strategy in patients with HBV replication and raised ALT levels, or those with high normal ALT levels and who are older than 40 years. 25 However, the current gold standard for the diagnosis of hepatic fibrosis is a liver biopsy which has several disadvantages, such as poor compliance, invasiveness, complications, and cost. 9 Therefore, noninvasive modalities of evaluating hepatic fibrosis have been proposed to overcome these problems. The two principal categories of noninvasive tests include serum fibrosis panels and hepatic elasticity imaging. 23 However, these modalities have not showed sufficient diagnostic efficacy for complete replacement of liver biopsy. 18 In the meantime, P2/MS, a new, accurate method, based only on a complete blood cell count, was developed for reflecting significant fibrosis (METAVIR F2-F4) and cirrhosis (METAVIR F4) in virus-related CLD. 17 Moreover, this was reconfirmed recently by two external comprehensive and prospective validation studies. 18, 19 However, a validation study is necessary before applying P2/MS to patients with HCC and our study is the first investigation to examine the diagnostic value of P2/MS in patients with HCC.
In this study, P2/MS detected significant fibrosis (METAVIR F2-F4) at a cut-off value <62 and effectively ruled out significant fibrosis (METAVIR F2-F4) at a cut-off value >115. This was consistent with the result of a P2/MS study by Lee et al. 17 However, for the detection of histological cirrhosis, P2/MS detected histological cirrhosis at a cut-off value < 30, and effectively ruled out histological cirrhosis at a cut-off value > 83. This was not consistent with a P2/MS study by Lee et al, 17 but was consistent with the cut-off values proposed by Kim et al. 18 Among our study population, chronic hepatitis B (CHB) patients were 93.6% and chronic hepatitis C (CHC) patients are only 6.4%. to be acceptable.
The AUROC of FIB-4 and GUCI were 0.704 and 0.717 for diagnosis of histological cirrhosis in our study, respectively.
These are somewhat inferior to previous reports for the FIB-4 and GUCI where AUROCs of 0.91 and 0.85 have been reported. 20, 21 The discrepancies seem to originate from the difference in study populations between our study and previous studies. CHB patients were dominant and a few CHC patients were enrolled in our study. In contrast, study populations of previous studies were composed of hepatitis C virus-infected patients only. Recently, it has been suggested that the pathogenesis of liver fibrosis in CHB is different from that of CHC, 26 in which the hepatic necroinflammatory activity of CHB is decreased after recurrent hepatitis B flares and HBeAg seroconversion is observed after the development of cirrhosis. 27 In contrast, CHC is a progressive disease with persistent inflammation that is related to liver cirrhosis. 27 Consequently, CHB has specific mechanisms for liver fibrosis and cirrhosis different from those of CHC. 27 Moreover, patients with space-occupying lesions such as HCC might have higher transaminase levels. 27 In addition, the fluctuating patterns of transaminase activity in patients with chronic viral hepatitis may be an important limitation for the use of noninvasive fibrosis scoring systems containing AST or ALT. 28 The diagnostic accuracy of P2/MS was not increased when analyzed according to tumor stage or the etiology of HCC. That might be related with small case numbers of our study and it made our study prone to type II errors. 29 
